Tabula Rasa HealthCare, Inc. (TRHC) Touches $55.04 High on Jun, 5; NantKwest, Inc. (NK) Had 4 Bullish Analysts

June 5, 2018 - By Ellis Scott

NantKwest, Inc. (NASDAQ:NK) Logo

Among 7 analysts covering NantKwest (NASDAQ:NK), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. NantKwest had 13 analyst reports since August 24, 2015 according to SRatingsIntel. The stock of NantKwest, Inc. (NASDAQ:NK) earned “Buy” rating by Canaccord Genuity on Tuesday, December 22. The stock has “Market Perform” rating by Raymond James on Thursday, June 2. The stock of NantKwest, Inc. (NASDAQ:NK) has “Overweight” rating given on Monday, August 24 by Piper Jaffray. Jefferies initiated NantKwest, Inc. (NASDAQ:NK) on Monday, August 24 with “Buy” rating. Jefferies downgraded the shares of NK in report on Tuesday, January 24 to “Hold” rating. The stock has “Hold” rating by Jefferies on Sunday, August 6. On Monday, August 24 the stock rating was initiated by Citigroup with “Buy”. The rating was downgraded by Citigroup to “Sell” on Tuesday, May 16. FBR Capital initiated it with “Outperform” rating and $30 target in Wednesday, October 28 report. On Monday, August 24 the stock rating was initiated by MLV with “Buy”. See NantKwest, Inc. (NASDAQ:NK) latest ratings:

11/12/2017 Broker: Raymond James Rating: Hold

The stock of Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) reached all time high today, Jun, 5 and still has $56.69 target or 3.00% above today’s $55.04 share price. This indicates more upside for the $1.10B company. This technical setup was reported by Barchart.com. If the $56.69 PT is reached, the company will be worth $33.03M more. The stock increased 1.83% or $0.99 during the last trading session, reaching $55.04. About 74,070 shares traded. Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) has risen 298.70% since June 5, 2017 and is uptrending. It has outperformed by 286.13% the S&P500. Some Historical TRHC News: ; 09/05/2018 – Tabula Rasa HealthCare Releases Research Results Re: Pharmacist-Led Pharmacogenomics (PGx) Services for PACE; 25/05/2018 – Tabula Rasa HealthCare President and Co-Founder Named A Fellow of the College of Physicians of Philadelphia; 08/05/2018 – Tabula Rasa HealthCare 1Q Loss/Shr 96c; 24/04/2018 – TABULA RASA HEALTHCARE INC – ANNOUNCED ITS OPTIMIZED OPIOID SOLUTION TO IDENTIFY & PREVENT UNINTENTIONAL OPIOID MISUSE & AVOID UNINTENTIONAL OVERDOSE; 13/03/2018 – Tabula Rasa HealthCare Chief Pharmacotherapy Officer Robert L. Alesiani to Receive American Pharmacists Association’s Hugo H. Schaefer Award; 12/03/2018 – TABULA RASA HEALTHCARE INC TRHC.O FY2018 REV VIEW $180.9 MLN — THOMSON REUTERS l/B/E/S; 12/03/2018 – Tabula Rasa HealthCare 4Q Adj EPS 9c; 24/04/2018 – Tabula Rasa HealthCare Launches its Optimized Opioid Solution™ to Predict and Prevent Unintentional Opioid Abuse; 24/05/2018 – Tabula Rasa HealthCare to Participate in Upcoming Investor Conferences; 04/04/2018 – CMS Changes to Medicare Part D Provide Potential Expansion of TRHC Medication Therapy Management Services for Medicare Advantage Plans

The stock increased 0.27% or $0.01 during the last trading session, reaching $3.74. About 43,092 shares traded. NantKwest, Inc. (NASDAQ:NK) has declined 8.37% since June 5, 2017 and is downtrending. It has underperformed by 20.94% the S&P500. Some Historical NK News: ; 23/04/2018 DJ NantKwest Inc, Inst Holders, 1Q 2018 (NK)

NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company has market cap of $292.05 million. The firm develops activated natural killer product candidates for the treatment of virally-induced cancers, such as polyoma virus induced merkel cell carcinoma, human papilloma virus induced cervical, and head and neck cancers; infectious diseases, including Ebola; and other serious viral, fungal, and bacterial infections. It currently has negative earnings. It is also develops high-affinity natural killer product candidates primarily for the treatment of solid tumors, breast cancer, head and neck/squamous, lymphoma, and various cancer; and target activated natural killer product candidates to treat hematological malignancies and solid tumors.

Among 3 analysts covering Tabula Rasa HealthCare (NASDAQ:TRHC), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Tabula Rasa HealthCare had 3 analyst reports since October 24, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Monday, October 24 by UBS. As per Monday, October 24, the company rating was initiated by Piper Jaffray. Wells Fargo initiated the shares of TRHC in report on Monday, October 24 with “Outperform” rating.

Analysts await Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) to report earnings on August, 6. They expect $0.08 EPS, up 188.89% or $0.17 from last year’s $-0.09 per share. TRHC’s profit will be $1.60M for 172.00 P/E if the $0.08 EPS becomes a reality.

Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>